Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

"Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of ST-246 and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty when SIGA will commence delivering any product or will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore,  SIGA has publicly stated it intends to appeal the Court of Chancery decision, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, to the extent that there is an appeal, we cannot predict how long that will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for SparVax ™, Valortim® and our rBChE products. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

-- Tables Follow --PHARMATHENE, INC. 

CONDENSED CONSOLIDATED BALANCE SHEETSMarch 31,December 31,20122011(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$

15,304,189$

11,236,771Accounts receivable (billed)1,146,3804,424,442Unbilled accounts receivable4,276,0753,021,208Prepaid expenses and other current assets802,080830,585Restricted cash-100,000Total current assets21,528,72419,613,006Property and equipment, net701,982788,666Other long term assets and deferred costs174,52553,384Goodwill2,348,4532,348,453Total assets$

24,753,684$

22,803,509LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Account
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Global Stem Cells Group today ... annual gathering of aesthetic medicine experts and innovators. GSCG ... introduce the company’s brand new training course that combines ... techniques. , The course is designed to address ... field, including facial aging caused by volume loss. ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... Global Stem Cells Group has announced ... April 27 - 29, 2015 in Boston. This world-class ... of stem cell research including applications, biology, medicine, regulations, ... , The conference will address recent developments in ... in stem cell therapies, regenerative medicine, tissue engineering, stem ...
Breaking Biology Technology:Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3
... 2 or 3 patients achieve undetectable HCV RNA levels, following 4 weeks of treatment with ... ... with Pegasys ... plus Copegus -, PRINCETON, N.J., Sept. 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces ...
... Whalen as Solutions Director. , ... ... [Symphony Management Consulting] announced that it has appointed A.J. Whalen ... from Wellesley Information Services (WIS) where he was responsible for ...
... helps visitors to electronica 2008 in Munich and covers topics such ... sources of pre-show information useful in planning a trip, online registration ... an extensive list of web links to travel, hotel, city and ... ...
Cached Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Immediate Release,Wednesday, October 28, 2009 Contact:,Robin Mackar, NIEHS,(919) ... Bisph Researchers studying the health effects of the chemical ... an integrated research initiative to produce data that will ... health effects. Researchers who just received funds ...
... 2009) Paved parking lots and driveways make our lives ... to reach underground water sources and alter the natural flow ... Agency today announced a study that will investigate ways to ... how water filters back into the ground. EPA is testing ...
... identified wheat and barley lines resistant to Crown Rot ... million in lost yield every year. Crown Rot, which ... caused by the fungus Fusarium . Dr Chunji ... using sophisticated screening methods to scan over 2400 wheat lines ...
Cached Biology News:NIEHS awards Recovery Act funds to address bisphenol A research gaps 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 8EPA's new green parking lot allows scientists to study permeable surfaces that may help the environment 2
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
Biology Products: